Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.59 |
| ▸ | PPARA | Q07869 | 15/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 7/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631311 | 0.82 | PPARG (0.55) | PPARGPPARAKDM4EPPARD | |
| SCHEMBL4389208 | 0.81 | PPARG (0.79) | PPARGPPARAPPARD | |
| SCHEMBL5757520 | 0.81 | PPARG (0.62) | PPARGPPARAKDM4EPPARDHRH3 | |
| SCHEMBL5730668 | 0.80 | PPARG (0.54) | PPARGPPARAPPARDHRH3 | |
| SCHEMBL5730014 | 0.79 | PPARG (0.53) | PPARGPPARAHRH3 | |
| SCHEMBL13916644 | 0.78 | PPARG (0.62) | PPARGPPARAKDM4EPPARDHRH3 | |
| SCHEMBL3283978 | 0.78 | PPARG (0.77) | PPARGPPARAPPARD | |
| SCHEMBL5349232 | 0.78 | PPARA (0.51) | PPARGPPARAPPARD | |
| SCHEMBL5738566 | 0.78 | PPARG (0.69) | PPARGPPARAPPARD | |
| SCHEMBL5738622 | 0.77 | PPARG (0.61) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313716-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016331-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |